Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Lung Neoplasms × Cancer Vaccines × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioma 2 Astrocytoma 2 Nervous System Neoplasms 1 Nervous System Diseases 1 Neoplasms 1 Neoplasm Metastasis 1 Lung Neoplasms 1 Glioblastoma 1 Central Nervous System Neoplasms 1 Central Nervous System Diseases 1 Brain Neoplasms 1 Brain Diseases 1 Adenocarcinoma 1

Interventions

pembrolizumab 33 Carboplatin 23 Radiotherapy 21 Paclitaxel 18 Cisplatin 18 Erlotinib Hydrochloride 16 Docetaxel 14 Pemetrexed 12 Nivolumab 11 Gemcitabine 11 osimertinib 10 Etoposide 9 Radiosurgery 8 durvalumab 7 Magnetic Resonance Spectroscopy 7 atezolizumab 6 Specimen Handling 6 Cyclophosphamide 6 Cetuximab 6 Taxes 5 Biopsy 5 Bevacizumab 5 130-nm albumin-bound paclitaxel 5 fludarabine 4 Ipilimumab 4 Immunoglobulin G 4 Gefitinib 4 Albumin-Bound Paclitaxel 4 spartalizumab 3 epacadostat 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03807102 2023-12-29

TVATLC01

Hunan Province Tumor Hospital

Phase 1/2 Unknown

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡